Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

BUSM awarded NCI EDRN, DOD grants to develop novel procedures for early detection of lung cancer

BUSM awarded NCI EDRN, DOD grants to develop novel procedures for early detection of lung cancer

UAB researchers pinpoint protein that causes nephrotic syndrome

UAB researchers pinpoint protein that causes nephrotic syndrome

EPO upholds Alnylam's Tuschl II 1407044 patent

EPO upholds Alnylam's Tuschl II 1407044 patent

Study reveals role of VSV in killing cancer cells through turning off major survival signal

Study reveals role of VSV in killing cancer cells through turning off major survival signal

Researchers show an oncolytic virus switches off cancer cell survival signal

Researchers show an oncolytic virus switches off cancer cell survival signal

Bacterial study confirms TLR2 signaling vital for activating human airway epithelial cells

Bacterial study confirms TLR2 signaling vital for activating human airway epithelial cells

Experts formulate research related to psychological adjustment and traumatic brain injury

Experts formulate research related to psychological adjustment and traumatic brain injury

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

BUSM professor wins 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research

BUSM professor wins 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Systemic amyloidosis patient to receive triple organ transplant

Systemic amyloidosis patient to receive triple organ transplant

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

New findings provide new clues on pathogenetic mechanisms of Alzheimer's disease

New findings provide new clues on pathogenetic mechanisms of Alzheimer's disease